- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00825487
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Translational Genomics Institute
-
-
California
-
Santa Monica, California, United States, 90404
- Premiere Oncology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
-
-
Nevada
-
Las Vegas, Nevada, United States, 89135
- Nevada Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to study-specific screening procedures
- A histologically or cytologically confirmed metastatic solid tumor or refractory/relapsed hematologic malignancy
- Have a life expectancy of at least 12 weeks
- ≥18 years of age
Measurable disease as defined by:
- Solid Tumors: Response Evaluation Criteria in Solid Tumors
Multiple Myeloma (MM): International Uniform Response Criteria, at least one of the following:
- Monoclonal protein in the plasma of ≥0.5 g/dL
- Monoclonal protein in the urine of ≥0.2 g/24 hr urine collection
- Serum immunoglobulin free light chain (FLC) ≥100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa to lambda FLC ratio
Malignant Lymphoma (ML): International Working Group Response Criteria
- At least one site of disease ≥2 cm in longest diameter (a lesion ≥1 cm can be considered if PET positive)
Chronic Lymphocytic Leukemia (CLL): NCI Working Group Guidelines
- Lymphocytosis (5 x 10^9 /L) with B-cell marker (CD19, CD20,CD23) + CD5
- High-risk characteristics (hemoglobin <10g/dL OR platelets <100 x 10^9 /L)
- Acute Myelogenous Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL): only patients with bone marrow or peripheral blast count of ≥20%
- Acute Promyelocytic Leukemia (APML): patients must be refractory to all-trans retinoic acid (ATRA) and arsenic trioxide
- Chronic Myelogenous Leukemia (CML): patients in blast crisis (bone marrow or peripheral blast count ≥20%) may be included if refractory to prior therapy and to any therapy the investigators deems of higher priority (for example, BCR-ABL inhibitors such as imatinib mesylate [Gleevec], nilotinib [Tasigna], or dasatinib [Sprycel])
- ECOG performance status ≤2
- Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 621 dose
- Females of childbearing potential must have a negative serum pregnancy test
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN) or ≤5.0 × ULN with metastatic liver disease
- Hemoglobin (Hgb) ≥10 g/dL (except in cases considered related to hematologic malignancy)
- Total bilirubin ≤1.5 × ULN
- Creatinine ≤1.5 x ULN (≤2.0 x ULN in cases considered related to multiple myeloma)
- Absolute neutrophil count ≥1.5 x 10^9/L (except in cases considered related to hematologic malignancy)
- Platelets ≥100 x 10^9/L (except in cases considered related to hematologic malignancy)
- Patients with hematologic malignancies who have progressed following at least two prior treatment regimens
Exclusion Criteria:
Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of the first dose
- In cases of hematologic malignancies, 4-week recovery from prior anticancer treatment is not required, however the patient must recover from prior treatment-related non-hematological toxicities to grade 2 or less
- When required for supportive care corticosteroids or hydroxyurea may be used
- Surgery within four weeks prior to the first dose
Known untreated brain metastases or leptomeningeal disease
- Patients with solid tumors who were treated for brain metastases and who have shown stable disease for at least 8 weeks prior to enrollment will be allowed
- Pregnant or breastfeeding
- Uncontrolled concurrent illness including, but not limited to ongoing or active symptomatic infection requiring systemic therapy, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
- Patients having a history of Thrombotic thrombocytopenic purpura (TTP) or Hemolytic-uremic syndrome (HUS) or HUS spectrum will be excluded from the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARQ 621 treatment
|
Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles.
ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 621 administered intravenously.
Time Frame: 24 months estimated
|
24 months estimated
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the pharmacokinetic profile of ARQ 621.
Time Frame: 24 months estimated
|
24 months estimated
|
To determine the pharmacodynamic profile (incl. biomarkers) of ARQ 621.
Time Frame: 24 months estimated
|
24 months estimated
|
To assess the preliminary anti-tumor activity of ARQ 621.
Time Frame: 24 months estimated
|
24 months estimated
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARQ 621-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingRefractory and/or Relapsed Metastatic Solid TumorsUnited States
-
University of Colorado, DenverUniversity of KentuckyCompletedRefractory Solid Tumors | Relapsed Solid TumorsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
-
TCRx Therapeutics Co.LtdRecruitingRefractory Solid Tumors | Relapsed Solid Tumors | TCR-T CellsChina
-
Stanford UniversityAmgen; Pediatric Oncology Experimental Therapeutics Investigators' ConsortiumCompletedRefractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed LeukemiaUnited States, Canada
-
Acrotech Biopharma Inc.Axis Clinicals LimitedTerminatedRelapsed/Refractory Solid Tumors/Hematological MalignanciesUnited States
-
Xinxiang medical universityRecruiting
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingRelapsed or Refractory Solid TumorsUnited States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Solid TumorsUnited States
Clinical Trials on ARQ 621
-
United BioPharmaTaipei Veterans General Hospital, TaiwanCompletedHerpes Simplex Virus InfectionTaiwan
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
Arcutis Biotherapeutics, Inc.CompletedPsoriasisCanada, United States
-
Arcutis Biotherapeutics, Inc.CompletedChronic Hand EczemaUnited States, Australia, Canada
-
National Cancer Institute (NCI)TerminatedEpithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural MesotheliomaUnited States
-
PfizerTerminatedSolid Tumor | Hematologic MalignanciesUnited States, Canada
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada
-
National Cancer Institute (NCI)CompletedChildhood Solid NeoplasmUnited States, Canada